Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TransMolecular Inc.

www.transmolecular.com

Latest From TransMolecular Inc.

TetraLogic appoints Jonathan Lloyd Jones CFO and vice-president

TetraLogic Pharmaceuticals, a biopharmaceutical company developing drugs to treat cancer, has appointed Jonathan Lloyd Jones chief financial officer and vice-president of corporate development. From 2006 to 2010 Mr Lloyd Jones served as vice-president of finance at TransMolecular, and prior to that he was a senior director of corporate development at Genzyme.

Cancer

Deals Shaping the Medical Industry (05/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Eisai boosts oncology research with two bioventure deals

Eisai has signed licensing and technology deals with two bioventures, both of which are aimed at strengthening its R&D activities in oncology, which the Japanese firm has positioned as a strategic therapeutic area amid patent expiries for its top product.

Cancer Neurology

Topaz Pharmaceuticals names Radie CEO

Topaz Pharmaceuticals has appointed Bob Radie president and chief executive officer. Dr Thomas Beck, who has been serving as interim CEO, will resume his role as chief medical officer. Mr Radie was most recently President and CEO of TransMolecular, a biotech company developing cancer diagnostic and treatment products. He has also previously served as Chief Business Officer at Prestwick Pharmaceuticals (which was acquired by Biovail in 2008) and Morphotek (acquired by Eisai in 2007). Topaz’s lead product is ivermectin topical cream, which is concluding Phase III trials to support an NDA for the treatment of head lice.

Cancer Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • TransMolecular Inc.
  • Senior Management
  • Contact Info
  • TransMolecular Inc.
    Phone: (610) 768-8041
    1060 1st Ave.
    Ste. 400
    King of Prussia, PA 19406
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register